TAK revenueFY2026¥4.51T
- FY YoY
- -1.7%
- 5Y CAGR
- +7.1%
TAK revenue was ¥4.51T for fiscal 2026 (ended Mar 31, 2026), down 1.7% from fiscal 2025. Compound annual growth was +7.1% over 5 years. It rose in 7 of the last 9 fiscal years.
Takeda Pharmaceutical Company Limited (TAK) financials
For fiscal 2026 (ended Mar 31, 2026), Takeda Pharmaceutical Company Limited reported ¥4.51T of revenue and -¥152.39B of net income. Figures are in JPY, the currency of its SEC filings.
- Revenue, FY2026
- ¥4.51T
- Revenue growth, YoY
- -1.7%
- Net income, FY2026
- -¥152.39B
- Net margin
- -3.4%
- Free cash flow, FY2026
- ¥865.43B
- EPS, diluted, FY2026
- -¥96.75
- Cash
- ¥595.05B
- Total debt
- ¥4.88T
FY2017FY2026
FY2017FY2026
FY2017FY2026
TAK revenue and earnings growth
TAK net incomeFY2026-¥152.39B
TAK net income was -¥152.39B for fiscal 2026 (ended Mar 31, 2026), compared with ¥107.93B in fiscal 2025.
TAK EPSFY2026-¥96.75
TAK diluted EPS was -¥96.75 for fiscal 2026 (ended Mar 31, 2026), compared with ¥67.23 in fiscal 2025.
TAK free cash flowFY2026¥865.43B
- FY YoY
- +1.1%
- 5Y CAGR
- -0.8%
TAK free cash flow was ¥865.43B for fiscal 2026 (ended Mar 31, 2026), up 1.1% from fiscal 2025. Compound annual growth was -0.8% over 5 years. It rose in 6 of the last 9 fiscal years.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥4.51T | ¥4.58T | ¥4.26T | ¥4.03T | ¥3.57T | ¥3.20T | ¥3.29T | ¥2.10T | ¥1.77T | ¥1.73T |
| Cost of revenue | ¥1.57T | ¥1.58T | ¥1.43T | ¥1.24T | ¥1.11T | ¥994.31B | ¥1.09T | ¥651.73B | ¥495.92B | ¥558.75B |
| Gross profit | ¥2.93T | ¥3.00T | ¥2.84T | ¥2.78T | ¥2.46T | ¥2.20T | ¥2.20T | ¥1.45T | ¥1.27T | ¥1.17T |
| Research and development | ¥675.92B | ¥730.23B | ¥729.92B | ¥633.33B | ¥526.09B | ¥455.83B | ¥492.38B | ¥368.30B | ¥325.44B | ¥312.30B |
| Selling, general and admin | ¥1.08T | ¥1.10T | ¥1.05T | ¥997.31B | ¥886.36B | ¥875.66B | ¥964.74B | ¥717.60B | ¥628.11B | ¥619.06B |
| Operating income | ¥6.22B | ¥342.59B | ¥214.07B | ¥490.50B | ¥460.84B | ¥509.27B | ¥100.41B | ¥237.69B | ¥241.79B | ¥155.87B |
| Interest expense | ¥148.12B | ¥137.31B | ¥119.53B | ¥116.97B | ¥122.43B | ¥130.81B | ¥149.01B | ¥48.16B | ¥10.04B | ¥7.56B |
| Pre-tax income | -¥142.35B | ¥175.08B | ¥52.79B | ¥375.09B | ¥302.57B | ¥366.24B | -¥60.75B | ¥127.61B | ¥217.21B | ¥143.35B |
| Income tax | ¥9.77B | ¥66.94B | -¥91.41B | ¥58.05B | ¥72.41B | -¥9.94B | -¥105.04B | -¥7.47B | ¥30.50B | ¥27.83B |
| Net income | -¥152.39B | ¥107.93B | ¥144.07B | ¥317.02B | ¥230.06B | ¥376.00B | ¥44.24B | ¥135.19B | ¥186.89B | ¥114.94B |
| EPS, basic | -¥96.75 | ¥68.36 | ¥92.09 | ¥204.29 | ¥147.14 | ¥240.72 | ¥28.41 | ¥140.61 | ¥239.35 | ¥147.15 |
| EPS, diluted | -¥96.75 | ¥67.23 | ¥91.16 | ¥201.94 | ¥145.87 | ¥238.96 | ¥28.25 | ¥139.82 | ¥237.56 | ¥146.26 |
| Diluted shares | 1.58B | 1.61B | 1.58B | 1.57B | 1.58B | 1.57B | 1.57B | 966.9M | 786.7M | 785.9M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | ¥595.05B | ¥385.11B | ¥457.80B | ¥533.53B | ¥849.70B | ¥966.22B | ¥637.61B | ¥702.09B | ¥294.52B | ¥319.45B |
| Receivables | ¥844.31B | ¥709.47B | ¥668.40B | ¥649.43B | ¥696.64B | ¥783.09B | ¥757.00B | ¥741.91B | ¥420.25B | - |
| Inventory | ¥1.40T | ¥1.22T | ¥1.21T | ¥986.46B | ¥853.17B | ¥753.88B | ¥759.60B | ¥919.67B | ¥212.94B | - |
| Current assets | ¥3.09T | ¥2.52T | ¥2.56T | ¥2.40T | ¥2.59T | ¥2.71T | ¥2.47T | ¥2.99T | ¥1.08T | - |
| Goodwill | ¥5.81T | ¥5.32T | ¥5.41T | ¥4.79T | ¥4.41T | ¥4.03T | ¥4.01T | ¥4.24T | ¥1.03T | - |
| Total assets | ¥15.51T | ¥14.25T | ¥15.11T | ¥13.96T | ¥13.18T | ¥12.91T | ¥12.82T | ¥13.79T | ¥4.11T | - |
| Current liabilities | ¥2.83T | ¥2.51T | ¥2.31T | ¥2.48T | ¥2.15T | ¥1.77T | ¥2.18T | ¥2.55T | ¥737.51B | - |
| Short-term debt | ¥512.16B | ¥548.94B | ¥367.25B | ¥339.60B | ¥203.99B | ¥22.15B | ¥586.82B | ¥984.95B | ¥18.00M | - |
| Long-term debt | ¥4.37T | ¥3.97T | ¥4.48T | ¥4.04T | ¥4.14T | ¥4.61T | ¥4.51T | ¥4.77T | ¥985.64B | - |
| Total debt | ¥4.88T | ¥4.52T | ¥4.84T | ¥4.38T | ¥4.35T | ¥4.64T | ¥5.09T | ¥5.75T | ¥985.66B | - |
| Total liabilities | ¥8.08T | ¥7.31T | ¥7.83T | ¥7.60T | ¥7.49T | ¥7.74T | ¥8.09T | ¥8.61T | ¥2.09T | - |
| Shareholders' equity | ¥7.43T | ¥6.94T | ¥7.27T | ¥6.35T | ¥5.69T | ¥5.18T | ¥4.73T | ¥5.19T | ¥2.02T | ¥1.95T |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | ¥1.04T | ¥1.06T | ¥716.34B | ¥977.16B | ¥1.12T | ¥1.01T | ¥669.75B | ¥328.48B | ¥377.85B | ¥261.36B |
| Capital expenditures | ¥176.00B | ¥200.79B | ¥175.42B | ¥140.66B | ¥123.25B | ¥111.21B | ¥127.08B | ¥77.68B | ¥67.00B | ¥61.66B |
| Free cash flow | ¥865.43B | ¥856.39B | ¥540.92B | ¥836.50B | ¥999.85B | ¥899.73B | ¥542.67B | ¥250.80B | ¥310.85B | ¥199.70B |
| Investing cash flow | -¥369.14B | -¥367.06B | -¥463.86B | -¥607.10B | -¥198.13B | ¥393.53B | ¥292.12B | -¥2.84T | -¥93.34B | -¥655.69B |
| Financing cash flow | -¥496.82B | -¥751.42B | -¥354.42B | -¥709.15B | -¥1.07T | -¥1.09T | -¥1.01T | ¥2.95T | -¥326.23B | ¥289.90B |
| Dividends paid | ¥311.90B | ¥302.50B | ¥287.19B | ¥279.42B | ¥283.67B | ¥283.36B | ¥282.58B | ¥142.95B | ¥141.89B | ¥141.69B |
| Share repurchases | ¥51.60B | ¥51.86B | ¥2.33B | ¥26.93B | ¥77.53B | ¥2.14B | ¥3.74B | ¥1.17B | ¥18.76B | ¥23.12B |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -1.7% | 7.5% | 5.9% | 12.8% | 11.6% | -2.8% | 56.9% | 18.5% | 2.2% | - |
| Net income growth, YoY | - | -25.1% | -54.6% | 37.8% | -38.8% | 749.9% | -67.3% | -27.7% | 62.6% | - |
| EPS growth, YoY | - | -26.3% | -54.9% | 38.4% | -39.0% | 745.9% | - | -41.1% | 62.4% | - |
| Gross margin | 65.1% | 65.5% | 66.5% | 69.1% | 69.0% | 68.9% | 66.9% | 68.9% | 72.0% | 67.7% |
| Operating margin | 0.1% | 7.5% | 5.0% | 12.2% | 12.9% | 15.9% | 3.1% | 11.3% | 13.7% | 9.0% |
| Net margin | -3.4% | 2.4% | 3.4% | 7.9% | 6.4% | 11.8% | 1.3% | 6.4% | 10.6% | 6.6% |
| Free cash flow margin | 19.2% | 18.7% | 12.7% | 20.8% | 28.0% | 28.1% | 16.5% | 12.0% | 17.6% | 11.5% |
| Return on equity | -2.1% | 1.6% | 2.0% | 5.0% | 4.0% | 7.3% | 0.9% | 2.6% | 9.3% | 5.9% |
| Return on assets | -1.0% | 0.8% | 1.0% | 2.3% | 1.7% | 2.9% | 0.3% | 1.0% | 4.6% | - |
| Current ratio | 1.09 | 1.01 | 1.11 | 0.97 | 1.21 | 1.53 | 1.13 | 1.17 | 1.46 | - |
| Debt to equity | 0.66 | 0.65 | 0.67 | 0.69 | 0.76 | 0.90 | 1.08 | 1.11 | 0.49 | - |
Source: XBRL data Takeda Pharmaceutical Company Limited files with the SEC, latest filing dated Jun 17, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
TAK peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TAK | ¥4.51T | -1.7% | -¥152.39B | -3.4% | $66.40B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| BMY | $50.03B | +4.2% | $9.24B | 18.5% | $127.01B |
| SNY | €43.63B | +6.2% | €7.81B | 17.9% | $114.71B |
TAK FAQ
9 questionsWhat is TAK revenue?
Takeda Pharmaceutical Company Limited (TAK) reported ¥4.51T of revenue for fiscal 2026 (ended Mar 31, 2026). That is down 1.7% from the year before.Is TAK profitable?
No. Takeda Pharmaceutical Company Limited reported a net loss of ¥152.39B for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does TAK have?
Takeda Pharmaceutical Company Limited reported ¥595.05B in cash and cash equivalents and ¥4.88T of debt on its most recent balance sheet in SEC filings.How fast is TAK revenue growing?
Takeda Pharmaceutical Company Limited's revenue changed -1.7% in fiscal 2026, to ¥4.51T. Its compound annual growth rate was +7.1% over 5 years.What is TAK gross margin?
Takeda Pharmaceutical Company Limited's gross profit was ¥2.93T on ¥4.51T of revenue for fiscal 2026 (ended Mar 31, 2026), a gross margin of 65.1%.What is TAK free cash flow?
Takeda Pharmaceutical Company Limited generated ¥865.43B of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of ¥1.04T less capital expenditures.What is TAK earnings per share?
Diluted earnings per share were -¥96.75 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did TAK last report financial results?
The latest statements here come from Takeda Pharmaceutical Company Limited's 20-F filed on Jun 17, 2026, covering the period ended Mar 31, 2026.Where does this TAK financial data come from?
Quantisnow builds these statements from the structured XBRL data Takeda Pharmaceutical Company Limited files with the SEC. It is provided for information only and is not investment advice.